Premium
The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial
Author(s) -
Wang Winfred,
Brugnara Carlo,
Snyder Cathie,
Wynn Lynn,
Rogers Zora,
Kalinyak Karen,
Brown Clark,
Qureshi Asif,
Bigelow Carolyn,
Neumayr Lynne,
SmithWhitley Kim,
Chui David H. K.,
Delahunty Mardee,
Woolson Rob,
Steinberg Martin,
Telen Marilyn,
Kesler Karen
Publication year - 2011
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08523.x
Subject(s) - hydroxycarbamide , placebo , medicine , clinical endpoint , double blinded , randomization , randomized controlled trial , magnesium , surgery , gastroenterology , disease , pathology , alternative medicine , materials science , metallurgy
Summary In a phase‐II multi‐centre double‐blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5–53 years old. Subjects were randomized to HC + placebo, Mg + placebo, HC + Mg, or placebo + placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8 weeks. Thirty‐six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso‐occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.